Establishment of more efficient validation of new therapies for Systemic Lupus Erythematosus (SLE) in mice
Reference number | |
Coordinator | Redoxis AB - Redoxis AB, Lund |
Funding from Vinnova | SEK 878 858 |
Project duration | January 2015 - August 2016 |
Status | Completed |
Important results from the project
This project aimed to validate and establish models for lupus in mice and to compare already established models with a new and faster model. Project proceeded according to plan and all work planned to be performed under this project are now performed.
Expected long term effects
In this project we wanted to compare a new and faster model for lupus in mice. This model is to our knowledge not commercially available and we will have a major advantage in being able to market such model. Also, animal studies can be shortened in time which will be beneficial to the mice included in the study. We could confirm the the new model certainly is faster than standard models and that this will be a major advantage in future studies.
Approach and implementation
Except for a short delay in getting all animals into our animal house, work has been proceeding as planned. We have been able to validate and compare the models and are now ready to market the models to our clients, both old and new. We also identified the need for in house capacity for histology and immunehistochemistry for follow up and evaluation of disease severity and spent some time to get protocols and procedures ready for commercial applications.